Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Lodise, Thomas P; Colman, Sam; Stein, Daniel S; Fitts, David; Goldberg, Lisa; Alexander, Elizabeth; Scoble, Patrick J; Schranz, Jennifer

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Issue Date

2020-05

Authors

Lodise, Thomas P

Colman, Sam

Stein, Daniel S

Fitts, David

Goldberg, Lisa

Alexander, Elizabeth

Scoble, Patrick J

Schranz, Jennifer

Abstract

Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

Citation

Lodise T, Colman S, Stein DS, Fitts D, Goldberg L, Alexander E, Scoble PJ, Schranz J. Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa145. doi: 10.1093/ofid/ofaa145. PMID: 32462049; PMCID: PMC7240345.